Ottani A, Leone S, Sandrini M, Ferrari A, Bertolini A (February 2006). “The analgesic activity of paracetamol is prevented by the blockade of cannabinoid CB1 receptors”. Eur. J. Pharmacol. 531 (1–3): 280–1. doi:10.1016/j.ejphar.2005.12.015. PMID16438952.
It is established that AM404 increases concentrations of the endogenous cannabinoid anandamide within the synaptic cleft, contributing to its analgesic activity.
AM404 was originally reported to be an endogenous cannabinoid reuptake inhibitor, preventing the transport of anandamide and other related compounds back from the synaptic cleft, much in the same way that common selective serotonin reuptake inhibitor (SSRI) antidepressants prevent the reuptake of serotonin. Earlier work on the mechanism of AM404 suggested that the inhibition of fatty acid amide hydrolase (FAAH) by AM404 was responsible for all of its attributed reuptake properties, since intracellular FAAH hydrolysis of anandamide changes the intra/extracellular anandamide equilibrium. However, this is not the case, as newer research on FAAH knockout mice has found that brain cells internalize anandamide through a selective transport mechanism which is independent of FAAH activity. It is this mechanism which is inhibited by AM404.
AM404 is also a TRPV1 agonist and inhibitor of cyclooxygenase COX-1 and COX-2, thus attenuating prostaglandin synthesis. AM404 is thought to induce its analgesic action through its activity on the endocannabinoid, COX, and TRPV systems, all of which are present in pain and thermoregulatory pathways.
Zygmunt, P. M.; Chuang, H.; Movahed, P.; Julius, D.; Högestätt, E. D. (2000-05-12). “The anandamide transport inhibitor AM404 activates vanilloid receptors”. European Journal of Pharmacology. 396 (1): 39–42. doi:10.1016/s0014-2999(00)00207-7. ISSN0014-2999. PMID10822052.
The anticonvulsant action is mediated through CB1 receptors.
Ottani A, Leone S, Sandrini M, Ferrari A, Bertolini A (February 2006). “The analgesic activity of paracetamol is prevented by the blockade of cannabinoid CB1 receptors”. Eur. J. Pharmacol. 531 (1–3): 280–1. doi:10.1016/j.ejphar.2005.12.015. PMID16438952.
Zygmunt, P. M.; Chuang, H.; Movahed, P.; Julius, D.; Högestätt, E. D. (2000-05-12). “The anandamide transport inhibitor AM404 activates vanilloid receptors”. European Journal of Pharmacology. 396 (1): 39–42. doi:10.1016/s0014-2999(00)00207-7. ISSN0014-2999. PMID10822052.